Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06181240
Other study ID # CR-005614
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 17, 2023
Est. completion date March 20, 2026

Study information

Verified date March 2024
Source Bolt Medical
Contact Timothy E. Meyer, PhD
Phone +1 760-392-3963
Email timothy@boltmed.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.


Description:

The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers with the Bolt Intravascular Lithotripsy System that was designed to percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium prior to full balloon dilatation at low pressures.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date March 20, 2026
Est. primary completion date April 20, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Subject is =18 years of age; - Subjects with native coronary artery disease (including stable or unstable angina and silent ischemia) suitable for Percutaneous Coronary Intervention (PCI); - For patients with unstable ischemic heart disease, a local site-based biomarker (preferably troponin or hs-troponin) must be less than or equal to the upper limit of lab normal (ULN) within 12 hours prior to the study procedure; - For patients with stable ischemic heart disease, CK-MB will be drawn at the time of the study procedure from the side port of the sheath; results need not be analyzed prior to enrollment, but must be less than or equal to the upper limit of lab normal (ULN); - Single de novo target lesion stenosis of protected LMCA, or LAD, RCA, or LCX (or of their branches) with: - Stenosis of =70% and <l00%; or - Stenosis =50% and <70% (visually assessed) with evidence of ischemia via positive stress test, or fractional flow reserve value =0.80, or iFR <0.90, or IVUS or OCT minimum lumen area =4.0 mm2; - Evidence of calcification at the target lesion site by - angiography, with fluoroscopic radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, or - Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), with presence of =270 degrees of calcium on at least 1 cross section; - Ability to pass a 0.014" guidewire across the lesion. Key Exclusion Criteria: - Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index procedure; - New York Heart Association (NYHA) class III or IV heart failure at time of index procedure; - Prospective need for hemodynamic support, i.e., IABP or Impella; - Chronic kidney disease with serum creatinine >2.5 mg/dL, eGFR <30 mL/min/1.73m2, or on chronic dialysis; - Unprotected left main diameter stenosis >50%; - Target vessel is excessively tortuous defined as the presence of two or more bends >90º or three or more bends >75º; - Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an unprotected left main lesion; - Chronic Total Occlusion; - Target lesion is located in a native vessel that can only be reached by going through a saphenous vein or arterial bypass graft;

Study Design


Intervention

Device:
Intravascular lithotripsy
Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.

Locations

Country Name City State
Netherlands Erasmus Medical Center Rotterdam
United Kingdom Royal Free Hospital London
United Kingdom St George's University of London London
United Kingdom St. Thomas' Hospital London

Sponsors (1)

Lead Sponsor Collaborator
Bolt Medical

Countries where clinical trial is conducted

Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Safety Endpoint Freedom from major adverse cardiac events (MACE) within 30 days following the index procedure. Within 30 days following procedure
Primary Primary Effectiveness Endpoint Procedural success defined as successful stent delivery with a final residual stenosis <50% (assessed by angiographic core laboratory) and freedom from in-hospital MACE. Immediately after the intervention/procedure/surgery
Secondary Device success The ability to deliver the Bolt IVL catheter across the target lesion, and delivery of lithotripsy without serious angiographic complications immediately after IVL. Immediately after the intervention/procedure/surgery
Secondary Angiographic success (at <50%) Stent delivery with <50% final residual stenosis and without serious angiographic complications. Immediately after the intervention/procedure/surgery
Secondary Procedural success Stent delivery with a final residual stenosis =30% and without in-hospital MACE. Immediately after the intervention/procedure/surgery
Secondary Angiographic success (at =30%) Stent delivery with =30% final residual stenosis and without serious angiographic complications. Immediately after the intervention/procedure/surgery
Secondary Serious angiographic complications Severe dissection (Type D to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow. Immediately after the intervention/procedure/surgery
Secondary MACE MACE within 6, 12, and 24 months. within 6, 12, and 24 months.
Secondary Target lesion failure (TLF) Cardiac death, target vessel myocardial infarction (TV-MI) (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods at 30 days, 6 months, 12 months, and 24 months. 30 days, 6 months, 12 months, and 24 months
Secondary All deaths, cardiac deaths, MIs, TV-MIs, procedural and nonprocedural MIs, ID-TVRs, ID-TLRs, non-ID-TLRs, non-ID-TVRs, all revascularizations (ID and non-ID), and stent thrombosis All deaths, cardiac deaths, MIs, TV-MIs, procedural and nonprocedural MIs, ID-TVRs, ID-TLRs, non-ID-TLRs, non-ID-TVRs, all revascularizations (ID and non-ID), and stent thrombosis (Academic Research Consortium (ARC) definite, probable, definite or probable). Periprocedure, within 30 days, 6 months, 12 months, and 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A